CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS-FTD Spectrum: A Systematic Narrative Review and Evidence Map.
Aasim Ali, Muhammad Arif, Usama Ashraf et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic narrative review examined the associations between cerebrospinal fluid (CSF) tau and amyloid biomarkers and cognitive impairment in 638 participants across the ALS-FTD spectrum. Total tau and p-tau181 showed significant correlations with cognitive outcomes, with total tau correlating with ECAS total (r = -0.398, P < 0.001) and ALS-specific cognition (r = -0.403, P < 0.001).
Key findings
- Total tau correlated with ECAS total (r = -0.398, P < 0.001) and ALS-specific cognition (r = -0.403, P < 0.001).
- Adjusted analyses showed p-tau181 associated with ECAS total (β = -0.03, p = 0.006) and memory performance (β = -0.04, p = 0.003).
- Lower Aβ42/Aβ40 was linked to poorer memory performance (β = 0.20, p = 0.044).
- Clinical and analytical heterogeneity prevented meta-analysis of the findings.
Why it matters
Understanding the role of CSF biomarkers in cognitive impairment across the ALS-FTD spectrum can help clinicians identify potential neurodegenerative processes and tailor management strategies, although current evidence is limited.
What to keep in mind
The study's findings are based on a limited number of observational studies with methodological heterogeneity, preventing a comprehensive meta-analysis.